March 20, 2020Open Access

Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Radiomics signatures predicted tumor sensitivity to treatment in patients with NSCLC, offering an approach that could enhance clinical decision-making to continue systemic therapies and forecast overall survival.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Dercle et al. (Fri,) studied this question.

synapsesocial.com/papers/69d98abf8988aeabbe685a52 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-19-2942

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Radiomic biomarkers for the prediction of immunotherapy outcome in patients with metastatic non-small cell lung cancer.2017 · 12 citations
2Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma2014 · 164 citations
3Random Forests2001 · 126,858 citations
4Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans2010 · 89 citations
5Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status2017 · 40 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo